Analyst Ratings For Adverum Biotechnologies Inc (NASDAQ:ADVM)
Today, Cantor Fitzgerald raised its price target on Adverum Biotechnologies Inc (NASDAQ:ADVM) to $8.00 per share.
There are 4 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Adverum Biotechnologies Inc (NASDAQ:ADVM) is Hold with a consensus target price of $8.50 per share, a potential 35.57% upside.
Some recent analyst ratings include
- 7/9/2019-Adverum Biotechnologies Inc (NASDAQ:ADVM) had its Buy rating reiterated by Cowen
- 6/13/2019-Adverum Biotechnologies Inc (NASDAQ:ADVM) has coverage initiated with a Mkt Perform ➝ Market Perform rating
- On 5/6/2019 James Paul Scopa, Director, bought 20,000 with an average share price of $6.71 per share and the total transaction amounting to $134,200.00.
- On 6/8/2015 Mehdi Gasmi, VP, sold 500 with an average share price of $38.64 per share and the total transaction amounting to $19,320.00.
- On 6/8/2015 Paul Wachter, Director, sold 1,192 with an average share price of $38.64 per share and the total transaction amounting to $46,058.88.
- On 5/26/2015 Paul Wachter, Director, sold 1,192 with an average share price of $36.94 per share and the total transaction amounting to $44,032.48.
- On 5/22/2015 Steven Daniel Schwartz, Director, sold 16,875 with an average share price of $38.38 per share and the total transaction amounting to $647,662.50.
- On 5/13/2015 Linda Bain, CFO, sold 285 with an average share price of $34.94 per share and the total transaction amounting to $9,957.90.
- On 5/13/2015 Mark S Blumenkranz, Director, sold 715 with an average share price of $34.94 per share and the total transaction amounting to $24,982.10.
Recent Trading Activity for Adverum Biotechnologies Inc (NASDAQ:ADVM)
Shares of Adverum Biotechnologies Inc closed the previous trading session at 6.16 −0.13 2.15% with 5.89 shares trading hands.
